MAUDE Adverse Event Report: BIOFIRE DIAGNOSTICS, LLC BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL

Model Number RIFT-ASY-0147

Device Problem False Negative Result (1225)

Patient Problem No Clinical Signs, Symptoms or Conditions (4582)

Event Date 02/12/2024

Event Type  malfunction  

Manufacturer Narrative

Investigation: the patient was a 65-year-old male who presented with signs and symptoms of abscess.On (b)(6) 2024, the patient's positive blood culture sample was tested on the biofire bcid2 panel.The biofire bcid2 panel reported all analytes as not detected.The biofire bcid2 panel was positive for meca/c and mrej (mrsa), but negative for s.Aureus and staphylococcus spp., resulting in a not detected result for 'meca/c and mrej (mrsa).' note that the biofire bcid2 panel will only report a detected result for 'meca/c and mrej (mrsa)' if s.Aureus, mrej, and meca/c assays are positive.Gram-positive clusters were observed on gram stain and mrsa was recovered from culture.On (b)(6) 2024, the sample was retested on the biofire bcid2 panel.The biofire bcid2 panel reported staphylococcus spp., s.Aureus, meca/c and mrej (mrsa) as detected.The customer reported that due to the biofire bcid2 panel result, the patient's treatment may have been delayed.They stated that the patient's wound was irrigated, and bacteremia was resolved.No serious injury or death was reported.Quality control (qc) records for pouch lot# 32kn23 (kit lot# 2635923) were reviewed.This pouch lot passed qc criteria and was found within specifications.The filmarray instrument (serial number (b)(6) was working within designed specifications.Conclusion: the investigation concluded that the most likely cause for the false negative mrsa result on the biofire bcid2 panel was a pouch anomaly.Biofire is continuously monitoring the manufacturing process and has controls in place to ensure the product is manufactured to the highest quality.Each biofire reagent lot is qualified prior to product release; this qualification includes a high statistical-confidence sampling to confirm that the kit components released for customer use are conforming.All qc metrics for the pouch lot and instrument were met, and they passed qc.Review of the associated instrument showed the instrument was performing within specification and was not expected to have contributed to the discrepancies observed by the customer.Overall, s.Aureus and staphylococcus on biofire bcid2 panel have a false negative rate of <0.001 in the field over the last year.These rates are within biofire system specifications.According to table 29.Biofire bcid2 panel clinical performance summary, staphylococcus spp.Of the biofire bcid2 panel instructions for use (ifu) (www.Online-ifu.Com/iti0048), the performance claim for the s.Aureus assay compared to standard manual and automated microbiological/biochemical identification methods showed an overall sensitivity of 100% (95% ci 97.6-100%) and an overall specificity of 99.9% (95% ci 99.5-100%).S.Aureus was detected in both false positive (fp) specimens using an additional molecular method.According to table 29.Biofire bcid2 panel clinical performance summary, staphylococcus spp.Of the biofire bcid2 panel ifu, the performance claim for the staphylococcus spp.Assay compared to standard manual and automated microbiological/biochemical identification methods showed an overall sensitivity of 99.8% (95% ci 98.9-100%) and an overall specificity of 98.8% (95% ci 98.0-99.3%).Staphylococcus spp.Was detected in all 13 fp specimens using an additional molecular method.

Event Description

Summary: (b)(6) center reported a potential false negative methicillin-resistant staphylococcus aureus (mrsa) result on the biofire blood culture identification 2 (bcid2) panel after testing a patient blood culture sample.Due to the biofire bcid2 panel result, the patient's treatment may have been delayed.No serious injury or death was reported.The investigation concluded that the most likely cause for the false negative mrsa result on the biofire bcid2 panel was a pouch anomaly.

• Brand Name: BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL
• Type of Device: BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL
• Manufacturer (Section D): BIOFIRE DIAGNOSTICS, LLC; 515 colorow dr; salt lake city UT 84108
• Manufacturer (Section G): BIOFIRE DIAGNOSTICS, LLC; 515 colorow dr; salt lake city UT 84108
• Manufacturer Contact: 515 colorow dr; salt lake city, UT 84108 ; 8017366354
• MDR Report Key: 19149419
• MDR Text Key: 341128485
• Report Number: 3002773840-2024-00303
• Device Sequence Number: 1
• Product Code: PAM
• UDI-Device Identifier: 00815381020338
• UDI-Public: 00815381020338
• Combination Product (y/n): N
• Reporter Country Code: US
• PMA/PMN Number: K193519
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Health Professional
• Reporter Occupation: Other Health Care Professional
• Type of Report: Initial
• Report Date: 04/19/2024

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Model Number: RIFT-ASY-0147
• Device Catalogue Number: RIFT-ASY-0147
• Device Lot Number: 2635923
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Initial Date Manufacturer Received: Not provided
• Initial Date FDA Received: 04/19/2024
• Was Device Evaluated by Manufacturer?: No
• Date Device Manufactured: 10/26/2023
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Age: 65 YR
• Patient Sex: Male